Subjects and methods: Final height; parentally adjusted final height; the metacarpal index (MI) SIB. the inner and outer diameters: and the total cross-sectional area (CSA). cortical CSA. medullary CSA and bone strength (Bending Breaking Resistance Index (BBRI)) were evaluated at the metacarpal site in two cohorts of GH-deficient children. treated with two different doses of GH. Group 1. (38 patients) was treated with 0.16 mg/kg body weight per week of GH and group 2 (37 patients) with 0.3 mg/kg per week. Results: At the end of treatment. with group 1 vs group 2. height SDS was -0.84 +/- 1.07 vs -0.46 +/- 0.76. and parentally adjusted height SDS was 0.14 +/- 1.08 vs 0.27 +/- 0.82. Parentally adjusted relative height gain was 1.14 +/- 0.89 vs 2.14 +/- 0.72 SDS (P < 0.000.1). MI SDS was 0.58 +/- 1.31. vs -0.42 +/- 1.54 (P < 0.005). MI SDS gain was 0.07 +/- 1.41 vs -0.35 +/- 1.85. There was no difference between groups in the outer and inner diameter, in the total and cortical CSAs, whereas medullary CSA was higher in group 2 (P < 0.05). BBRI was 10.02 +/- 5.37 vs 11.52 +/- 5.49cm(3), and BBRI gainwas 3.33 +/- 5.06 vs 6.88 +/- 6.65 (P=0.01). P values were assessed using student's t-test. Conclusion: Higher GH doses result in a greater height gain and improved bone strength.

Influence of two different GH dosage regimens on final height, bone geometry and bone strength in GH-deficient children.

BOZZOLA, MAURO;
2006-01-01

Abstract

Subjects and methods: Final height; parentally adjusted final height; the metacarpal index (MI) SIB. the inner and outer diameters: and the total cross-sectional area (CSA). cortical CSA. medullary CSA and bone strength (Bending Breaking Resistance Index (BBRI)) were evaluated at the metacarpal site in two cohorts of GH-deficient children. treated with two different doses of GH. Group 1. (38 patients) was treated with 0.16 mg/kg body weight per week of GH and group 2 (37 patients) with 0.3 mg/kg per week. Results: At the end of treatment. with group 1 vs group 2. height SDS was -0.84 +/- 1.07 vs -0.46 +/- 0.76. and parentally adjusted height SDS was 0.14 +/- 1.08 vs 0.27 +/- 0.82. Parentally adjusted relative height gain was 1.14 +/- 0.89 vs 2.14 +/- 0.72 SDS (P < 0.000.1). MI SDS was 0.58 +/- 1.31. vs -0.42 +/- 1.54 (P < 0.005). MI SDS gain was 0.07 +/- 1.41 vs -0.35 +/- 1.85. There was no difference between groups in the outer and inner diameter, in the total and cortical CSAs, whereas medullary CSA was higher in group 2 (P < 0.05). BBRI was 10.02 +/- 5.37 vs 11.52 +/- 5.49cm(3), and BBRI gainwas 3.33 +/- 5.06 vs 6.88 +/- 6.65 (P=0.01). P values were assessed using student's t-test. Conclusion: Higher GH doses result in a greater height gain and improved bone strength.
2006
The Pediatrics category covers resources on all aspects of clinical medicine in pediatrics. Pediatric specialties including cardiology, dermatology, gastroenterology, hematology, immunology and infectious diseases, neurology, nutrition, oncology, psychiatry, surgery, tropical medicine, urology, and nephrology are also included. Resources concerned with neonatology and adolescent medicine are also covered.
Esperti anonimi
Inglese
Internazionale
STAMPA
154
3
479
482
4
bone density; growth hormone; growth hormone deficiency
no
5
info:eu-repo/semantics/article
262
Radetti, G; D'Addato, G; Gatti, D; Bozzola, Mauro; Adami, S.
1 Contributo su Rivista::1.1 Articolo in rivista
none
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11571/103601
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 11
social impact